- |||||||||| everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
The TEAMMATE Trial: Post-Transplant Outcomes and Social Determinants of Health (Forum Hall) - Jan 9, 2024 - Abstract #ISHLT2024ISHLT_535;
Treatment effects according to subgroups defined by SDOH including Child Opportunity Index will be available at presentation.Conclusion In the TEAMMATE Trial, major adverse HT events were more common in those with public insurance and in Hispanic and Black participants. Health-related QOL in this cohort was high irrespective of SDOH.
- |||||||||| Augtyro (repotrectinib) / BMS
Biomarker, Clinical, Observational data, Retrospective data, Review, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal, Metastases: ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report. (Pubmed Central) - Jan 8, 2024
We demonstrate that CELF4 is dysregulated in PanNETs, where it influences tumor development and aggressiveness, likely by modulating the mTOR pathway, suggesting its potential as therapeutic target. To the best of our knowledge, we reported the first case demonstrating anti-tumor activity of repotrectinib in a patient with AC carring an ETV6-NTRK3 gene fusion, indicating that repotrectinib may be an efficient therapeutic option for tumors with NTRK gene rearrangements.
- |||||||||| everolimus / Generic mfg.
Journal: Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma. (Pubmed Central) - Jan 4, 2024
In clinical samples, high expression of WSB2 was associated with low wild-type p53 expression and high p-mTOR expression. These findings demonstrate that WSB2 is overexpressed and degrades wild-type p53 and then activates the IGFBP3-AKT/mTOR axis, leading to HCC tumorigenesis and lung metastasis, which indicates that targeting mTOR could be a new therapeutic strategy for HCC patients with high WSB2 expression and wild-type p53.
- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Metastases: CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) - Jan 3, 2024
P1, N=12, Active, not recruiting,
These findings demonstrate that WSB2 is overexpressed and degrades wild-type p53 and then activates the IGFBP3-AKT/mTOR axis, leading to HCC tumorigenesis and lung metastasis, which indicates that targeting mTOR could be a new therapeutic strategy for HCC patients with high WSB2 expression and wild-type p53. Trial completion date: Jan 2024 --> Jan 2025
- |||||||||| everolimus / Generic mfg.
Journal: Everolimus-induced hyperpermeability of endothelial cells causes lung injury. (Pubmed Central) - Jan 2, 2024
Consistent with in vitro data, everolimus treatment caused a visible lung-vascular barrier dysfunction, including an increase in protein in BALF and lung capillary-endothelial permeability, which was significantly attenuated by pretreatment with an inhibitor of PKC?, MLCK, and ryanodine. This study shows that everolimus induced pulmonary endothelial hyper-permeability, at least partly, in an MLC phosphorylation-mediated EC contraction which is influenced in a Ca-dependent manner and can lead to lung injury through mTOR-independent mechanisms.
- |||||||||| everolimus / Generic mfg.
Journal: Long and Short-Term Effect of mTOR Regulation on Cerebral Organoid Growth and Differentiations. (Pubmed Central) - Dec 28, 2023
This study shows that everolimus induced pulmonary endothelial hyper-permeability, at least partly, in an MLC phosphorylation-mediated EC contraction which is influenced in a Ca-dependent manner and can lead to lung injury through mTOR-independent mechanisms. These data suggest that the optimal activity of mTOR is crucial in maintaining normal brain development, and its role is not confined to the early neurogenic phase of brain development.
- |||||||||| everolimus / Generic mfg., sirolimus / Generic mfg.
Journal: mTORC1 regulates the metabolic switch of postnatal cardiomyocytes during regeneration. (Pubmed Central) - Dec 24, 2023
This indicates that mTORC1 inhibition following injury accelerates the postnatal metabolic switch, which promotes metabolic maturation and impedes cardiomyocyte proliferation and heart regeneration. Taken together, our results define an important role for mTORC1 in regulating postnatal cardiac metabolism and may represent a novel target to modulate cardiac metabolism and promote heart regeneration.
- |||||||||| everolimus / Generic mfg.
Review, Journal: The Evolving Landscape of Therapeutics for Epilepsy in Tuberous Sclerosis Complex. (Pubmed Central) - Dec 23, 2023
The review is narrative in nature, without any date restrictions, and summarizes the most relevant literature on the neurological aspects and management of TSC. By consolidating the current understanding of TSC neurobiology and evidence-based treatment strategies, this review provides an invaluable reference that highlights progress made while also emphasizing areas requiring further research to optimize care and outcomes for TSC patients.
- |||||||||| everolimus / Generic mfg.
Journal: Silver Nanoparticles (AgNPs) as Enhancers of Everolimus and Radiotherapy Sensitivity on Clear Cell Renal Cell Carcinoma. (Pubmed Central) - Dec 23, 2023
Moreover, 786-O is intrinsically resistant to radiation, but after AgNPs' administration, radiation induces cytotoxicity through mitochondrial membrane depolarization and S phase blockage. These results demonstrate AgNPs' cytotoxic potential against ccRCC and seem promising regarding the combination with Everolimus and sensitization to radiotherapy, which can, in the future, benefit ccRCC patients' management.
- |||||||||| Trial completion date, Trial primary completion date, Metastases: FUTURE-SUPER: An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (clinicaltrials.gov) - Dec 22, 2023
P2, N=139, Active, not recruiting,
These results demonstrate AgNPs' cytotoxic potential against ccRCC and seem promising regarding the combination with Everolimus and sensitization to radiotherapy, which can, in the future, benefit ccRCC patients' management. Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> May 2023
- |||||||||| DFF332 / Novartis
Enrollment closed, Enrollment change, Combination therapy, IO biomarker, Metastases, Immuno-oncology: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (clinicaltrials.gov) - Dec 22, 2023
P1, N=40, Active, not recruiting,
Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> May 2023 Recruiting --> Active, not recruiting | N=180 --> 40
- |||||||||| everolimus / Generic mfg.
Enrollment closed: Everolimus Trial in Laryngotracheal Stenosis (clinicaltrials.gov) - Dec 20, 2023
P1, N=20, Active, not recruiting,
Recruiting --> Active, not recruiting | N=180 --> 40 Recruiting --> Active, not recruiting
- |||||||||| cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
Journal: Influence of immunosuppressive drugs on natural killer cells in therapeutic drug exposure in liver transplantation. (Pubmed Central) - Dec 20, 2023
Recruiting --> Active, not recruiting Immunosuppression consists of a triple drug standard regimen comprising tacrolimus (TAC) and corticosteroids (CS) with either mycophenolate mofetil (MMF) or sirolimus (SIR)/everolimus (EVE)...Drug type and concentration: single drug [EVE, 5 ng/mL; SIR, 5 ng/mL; TAC, 5 ng/mL; cyclosporine A (CSA), 125 ng/mL; MMF, 15
- |||||||||| everolimus / Generic mfg.
Impact of [18F]AlF-NOTA-octreotide PET/CT on the therapeutic management of neuroendocrine tumor patients. (Teun - Hilton Antwerp Old Town) - Dec 19, 2023 - Abstract #BWG2024BWG_150;
In total, [18F]AlF-OC PET/CT impacted clinical management in 10/75 patients (13.3%), leading to a major difference in 7/10 cases (follow up for 7/7 patients based on [68Ga]Ga-DOTA-SSA PET/CT vs. switch to PRRT for five; switch to everolimus for one and start SSA for one patient based on [18F]AlF-OC PET/CT) and a minor change in 3/10 cases (follow-up for [68Ga]Ga-DOTA-SSA PET/CT vs. SSA dose escalation for [18F]AlF-OC)...Differences in clinical management were seen in 10 patients (13.3%), which were all cases of therapy intensification driven by higher number of lesions detected by [18F]AlF-OC PET/CT. The use of [18F]AlF-OC did not impact TNM staging or clinical management in the large majority of the patients (86.7%), further validating the potential for routine clinical use of [18F]AlF-OC PET/CT instead of [68Ga]Ga-DOTA-SSA PET/CT.
- |||||||||| cholestyramine (A3384) / Ipsen, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sutent (sunitinib) / Pfizer
Diarrhea is not a VIP guest (Sancy - Hilton Antwerp Old Town) - Dec 19, 2023 - Abstract #BWG2024BWG_45;
A combination of treatment with loperamide, pancreatic enzyme supplementation and codein syrup resulted in a mild reduction in diarrhea...For liver-dominant disease, targeted treatment is recommended, such as bland embolization, radiofrequency ablation, and radioembolization. Other treatments such as Everolimus, Sunitinib, peptide receptor radionuclide therapy (PRRT) or chemotherapy are alternatives for metastatic or unresectable disease.
- |||||||||| Zolinza (vorinostat) / Merck (MSD), Torisel (temsirolimus) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date, Epigenetic controller, Metastases: Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer (clinicaltrials.gov) - Dec 19, 2023
P1, N=249, Active, not recruiting,
Other treatments such as Everolimus, Sunitinib, peptide receptor radionuclide therapy (PRRT) or chemotherapy are alternatives for metastatic or unresectable disease. Unknown status --> Active, not recruiting | Trial completion date: May 2021 --> Aug 2025 | Trial primary completion date: May 2020 --> Aug 2025
- |||||||||| Cytovene (ganciclovir) / Roche
Retrospective data, Journal: Reliability of QuantiFERON (Pubmed Central) - Dec 17, 2023
Patients who are initially at high risk of significant cellular rejection may benefit from induction therapy. In the population of heart transplant recipients, most of whom received ATG-based induction, the QuantiFERON
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Real world data on treatment of chromophobe renal cell carcinoma. (Level 1, West Hall; Poster Bd # G12) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_753;
No standardized treatment for metastatic disease could be identified. Overall treatment duration was comparable to clear cell carcinoma.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial. (Level 3, Ballroom) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_162;
P3
Clinical Trial Registration Number: NCT02811861 Sponsored by Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Background: In the primary analysis of the phase 3 open-label CLEAR trial, lenvatinib + pembrolizumab (L+P) showed statistically significant and clinically meaningful improvements in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) compared with sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) (Motzer NEJM 2021)... 1069 treatment-na
- |||||||||| Review, Journal: Anti-CMV therapy, what next? A systematic review. (Pubmed Central) - Dec 6, 2023
Maribavir and letermovir are the latest antivirals to have been developed with other targets...Molecules with a direct action against HCMV include brincidofovir, cyclopropavir and anti-terminase benzimidazole analogs...Immunomodulating molecules such as leflunomide and everolimus have also demonstrated indirect antiviral activity against HCMV and could be an interesting complement to antiviral therapy...All these molecules have shown anti-HCMV potential as monotherapy or in combination with others. These new approaches could be interesting to validate in clinical trials.
- |||||||||| everolimus / Generic mfg.
Journal: Unfolding the role of the PI3K/AKT/MTOR pathway in male breast cancer: A pragmatic appraisal. (Pubmed Central) - Dec 5, 2023
In the setting of estrogen-dependent metastatic disease, the use of everolimus has been seldom reported, although the PI3K/AKT/mTOR pathway seems to be a critical oncogenic driver. This paper dissects hallmark biological features of ER+/HER2-advanced male breast cancer, setting a comprehensive basis to promote personalized care, focusing on the potential of targeting the PI3K/AKT/mTOR pathway.
- |||||||||| Disalcid (salsalate) / Bausch Health
Review, Journal: Salsalate: a pleotropic anti-inflammatory drug in the treatment of diabetes, obesity, and metabolic diseases. (Pubmed Central) - Dec 4, 2023
Long-term safety and efficacy of Salsalate in the treatment of T2DM have been evaluated, which showed improved fasting plasma glucose and reduced HbA1C levels as well as reduced pro-inflammatory markers in T2DM patients. Current publication summarizes the literature review of pathophysiology of role of inflammation in T2DM and clinical efficacy and safety of Salsalate in the treatment of T2DM.
- |||||||||| camizestrant (AZD9833) / AstraZeneca, Undisclosed CDK4/6 inhibitor / CS Group
Journal: The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance. (Pubmed Central) - Dec 4, 2023
Evaluation of camizestrant in combination with CDK4/6i (palbociclib or abemaciclib) in CDK4/6-naive and -resistant models, as well as in combination with PI3K?i (alpelisib), mTORi (everolimus), or AKTi (capivasertib), indicated that camizestrant was active with CDK4/6i or PI3K/AKT/mTORi and that antitumor activity was further increased by the triple combination...The response was observed independently of PI3K pathway mutation status. Overall, camizestrant shows strong and broad anti-tumor activity in ER+ breast cancer as a monotherapy and when combined with CDK4/6i and PI3K/AKT/mTORi.
|
